Protein Phosphatase 2A Interacts with and Directly Dephosphorylates RelA
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Nuclear factor-kappa B (NF-kappa B)/Rel transcription factors are key regulators of a variety of genes involved in inflammatory responses, growth, differentiation, apoptosis, and development. There are increasing lines of evidence that NF-kappa B/Rel activity is controlled to a great extent by its phosphorylation state. In this study, we demonstrated that RelA physically associated with protein phosphatase 2A (PP2A) subunit A (PR65). Both the N- and C-terminal regions of RelA were responsible for the PP2A binding. RelA co-immunoprecipitated with PP2A in melanocytes in the absence of stimulation, indicating that RelA forms a signaling complex with PP2A in the cells. RelA was dephosphorylated by a purified PP2A core enzyme, a heterodimer formed by the catalytic subunit of PP2A (PP2Ac) and PR65, in a concentration-dependent manner. Okadaic acid, an inhibitor of PP2A at lower concentration, increased the basal phosphorylation of RelA in melanocytes and blocked the dephosphorylation of RelA after interleukin-1 stimulation. Interestingly, PP2A immunoprecipitated from melanocytes was able to dephosphorylate RelA, whereas PP2A immunoprecipitated from melanoma cell lines exhibited decreased capacity to dephosphorylate RelA in vitro. Moreover, in melanoma cells in which I kappa B kinase activity was inhibited by sulindac to a similar level as in melanocytes, the phosphorylation state of RelA and the relative NF-kappa B activity were still higher than those in normal melanocytes. These data suggest that the constitutive activation of RelA in melanoma cells (Yang, J., and Richmond, A. (2001) Cancer Res. 61, 4901-4909) could be due, at least in part, to the deficiency of PP2A, which exhibits decreased dephosphorylation of NF-kappa B/RelA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This can be owed to higher PP2A activity in CIP2A deficient cells leading to dephosphorylation of RelA and inactivation of the NF-kB downstream signalling (35,36).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Function and Activation of NF-kappaB in the Immune System
Baeuerle, P. A., & Henkel, T. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.001041 · Cited by 4,745
An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation.
Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., & Miyamoto, S. (1995) · Genes & Development · doi:10.1101/gad.9.22.2723 · Cited by 1,724
Research works printed but not linked: 5
- Rodriguez, 1996, Oncogene, 12, 2425
- Thevenin, 1990, New Biol., 2, 793
- Yang, 2001, Cancer Res., 61, 4901
- Gilmore, 1996, Oncogene, 13, 1367
- Sovak, 1997, J. Clin. Invest., 100, 2952, 10.1172/JCI119848 · DOI · Paper page
Cited by
Items 101–131 of 131
Ozaki, A., Morimoto, H., Tanaka, H., Okamura, H., Yoshida, K., Amorim, B. R., & Haneji, T. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20873 · Cited by 12
“Indeed, PP2A is physically associated with p65NF-kB in unstimulated melanocytes and is able to dephosphorylate p65NF-kB after IL-1 stimulation [Yang et al., 2001].”
BackgroundPKA negatively regulates PP2Cβ to activate NF-κB-mediated inflammatory signaling
Choi, H.-K., Park, S., Oh, H.-J., Han, E.-J., Lee, Y., Lee, J., Jun, W. J., Choi, K., & Yoon, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.129 · Cited by 12
Ben-Crentsil, N. A., Ismail, W. M., Balasis, M. E., Newman, H., Quintana, A., Binder, M., Kruer, T. L., Neupane, S., Ferrall‐Fairbanks, M. C., Fernandez, J. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0093 · Cited by 10
Rietz, A., Volkov, Y., Davies, A., Hennessy, M., & Spiers, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01559.x · Cited by 10
“When we investigated this further, it was found that OA increased phosphorylation of NF-kB (Ser(536)), which is not unexpected as PP2A de-phosphorylates the p65 subunit of NF-kB in vitro (Yang et al., 2001).”
BackgroundRole of protein phosphatase 2A in kidney disease (Review)
Shao, L., Ma, Y., Fang, Q., Huang, Z., Wan, S., Wang, J., & Yang, L. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10671 · Cited by 10
Sun, L., Pappy, A. L., Pham, T., & Shanley, T. P. (2015) · Biomolecules · doi:10.3390/biom5031284 · Cited by 12
“Moreover, direct interaction and dephosphorylation of RelA with PP2A was demonstrated in Sulindac treated melanoma cells [39].”
BackgroundLoss of calreticulin function decreases NFκB activity by stabilizing IκB protein
Massaeli, H., Jalali, S., Viswanathan, D., & Mesaeli, N. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.017 · Cited by 8
Lou, P., Lucchinetti, E., Hersberger, M., Clanachan, A. S., & Zaugg, M. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004295 · Cited by 6
Regulation of signal transduction by spatial parameters: a case in NF– κ B oscillation
Ichikawa, K., Ohshima, D., & Sagara, H. (2015) · IET Systems Biology · doi:10.1049/iet-syb.2013.0020 · Cited by 6
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0622 · Cited by 5
Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5
Seumen, C. H. T., Tomasiunaite, U., Legler, D. F., & Hauck, C. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-03618-9 · Cited by 4
Serine/Threonine Protein Phosphatases in Apoptosis
Gausdal, G., Krakstad, C., Herfindal, L., & Døskeland, S. O. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-199-4_7 · Cited by 3
Role of PP2A in Cancer and Signal Transduction
Walter, G. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50465-4 · Cited by 3
Huang, Y., He, Y., Wang, Z., Zhang, F., Han, M., Guo, X., Xie, Y., Wang, J., Ma, X., Dan, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116899 · Cited by 2
TRANSCRIPTOMIC EFFECTS OF TET-ON AND MIFEPRISTONE INDUCIBLE SYSTEMS IN MOUSE LIVER
Reboredo, M., Kramer, M. G., Smerdou, C., Prìeto, J., & Rivas, J. D. L. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.057 · Cited by 2
Redox signaling in regenerative medicine: Regulatory mechanisms and therapeutic implications
Sharifi, A. M., Sharifi, M. A., & Kamarul, T. (2024) · Advances in biogerontology · doi:10.1016/bs.abger.2024.05.001 · Cited by 1
LTF regulates glioblastoma progression and temozolomide resistance via the NF-κB signaling pathway
Gao, L., Xiao, H., Lu, H., Ma, J., & Zhu, H. (2025) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2025e13821 · Cited by 1
Silverstein, A. M., Davis, A. J., Bielinski, V. A., Esplin, E. D., Mahmood, N. A., & Mumby, M. C. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50550-7 · Cited by 2
Post-translational modification of NF-kB: regulation of stability and gene expression
Hertlein, E. K. (2006) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Ação anti-inflamatória da insulina
Mittestainer, F. C. (2011) · doi:10.47749/t/unicamp.2011.849615
Data from Systemic Targeting Inhibitor of κB Kinase Inhibits Melanoma Tumor Growth
Yang, J., Pan, W., Clawson, G. A., & Richmond, A. J. (2023) · doi:10.1158/0008-5472.c.6494753
Self-citationData from Systemic Targeting Inhibitor of κB Kinase Inhibits Melanoma Tumor Growth
Yang, J., Pan, W., Clawson, G. A., & Richmond, A. J. (2023) · doi:10.1158/0008-5472.c.6494753.v1
Self-citationCvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H. J., Bützow, R. C., Haglund, C. H., Kaipio, K., Arsiola, T., et al. (2023) · doi:10.1158/1535-7163.c.6543912
Fang, X., Wen, X., Zhang, H., & Chen, Z. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-07963-w · Cited by 1
Nyback, K., Alfonso, A., Alvariño, R., Suzuki, T., Watanabe, R., Uchida, H., Vieytes, M. R., & Botana, L. M. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04320-3 · Cited by 1
“The function of PP2A in this process is to dephosphorylate NFκB to regulate its activ - ity and avoid hyperphosphorylation (Yang et al. 2001).”
Sripada, A., Varma, R., Sirohi, K., Sahu, A., Verma, M., & Alam, R. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkaf343 · Cited by 1
Fu, S.-T., Hsiao, G., Li, C.-H., Chan, Y.-J., Hsu, T.-J., Kung, Y.-C., Cheng, Y., & Lee, C. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154449
Phosphoregulation of interleukin-1 receptor-associated kinase 1 in inflammatory signaling
Suresh, M., Vaz, C. E., Dcunha, L., Raju, R., Pinto, S. M., & Kanekar, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1937314
“The IRAK1-speci fi c regulatory function of PP2A is especially important, given that PP2A is broadly recognized as a negative regulator of in fl ammatory signaling, directly dephosphorylating RelA (65), IKK b (66), and members of the MAPK family (67, 68).”
Exploring the Role of EBP50 in Vascular Inflammation
Leslie, K. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Metadata
- Authors
- Yang, J., Fan, G.-H., Wadzinski, B. E., Sakurai, H., & Richmond, A.
- Affiliations
- Vanderbilt University (US)
- United States Department of Veterans Affairs (US)
- Corresponding author
- Richmond, Ann
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 276
- Issue
- 51
- Pages
- 47828-47833
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2665282
- OpenAlex
- W1523852619
- Cited by
- 130
- References
- 51
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 8 · 2018: 1 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 7 · 2013: 9 · 2012: 2
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6877 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA 34590, CA56740, CA68485, R01CA034590, R01CA056704, P30CA068485)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- protein phosphatase 2A, RelA, NF-κB, dephosphorylation, PP2A catalytic subunit, protein-protein interaction, melanocytes, melanoma, IκB kinase, sulindac, interleukin-1, okadaic acid
- MeSH terms
- Humans, Ligases, Melanoma, Phosphoprotein Phosphatases, Phosphorylation, Protein Binding, Tumor Cells, Cultured, NF-kappa B, Protein Phosphatase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.